Clinical Trial

The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).

Name: The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P). — clinical trial record (NCT07617012)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A Phase I Study to Assess the Safety, Tolerability and Efficacy of dopaminergic neural progenitor cells (XS411CN cell injection) for the treatment of multiple system atrophy Parkinsonian variant (MSA-P).

Trial Details

NCT Number	NCT07617012
Lead Sponsor	XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Conditions	the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P)
Enrollment	3 participants
Start Date	2026-06-15
Primary Completion	2026-08-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-01